Related Experiment Video
Updated: May 9, 2026

Heterotypic Three-dimensional In Vitro Modeling of Stromal-Epithelial Interactions During Ovarian Cancer Initiation and Progression
Published on: August 28, 2012
Activation of apoptotic pathway in normal, cancer ovarian cells by epothilone B
Aneta Rogalska1, Ewa Szula1, Arkadiusz Gajek1
1Department of Thermobiology, Institute of Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, 90-236 Lodz, Poland.
Abstract:
The epothilones, a new class of microtubule-targeting agents, seem to be a very promising alternative to the current strategy of cancer treatment. We have analyzed the aspects of epothilone B (Epo B) on cellular metabolism of tumor (OV-90) and normal (MM 14) ovarian cells. The observed effects were compared with those of paclitaxel (PTX), which is now a standard for the treatment of ovarian cancer. The results provide direct evidence that Epo B is considerably more cytotoxic to human OV-90 ovarian cancer cells than PTX. We have found, that antitumor efficacy of this new drug is related to its apoptosis-inducing ability, which was confirmed during measurements typical markers of the process. Epo B induced changes in morphology of cells, mitochondrial membrane potential and cytochrome c release. Also a slight increase of the intracellular calcium level was observed. Moreover, we have found that ROS production, stimulated by Epo B, is directly involved in the induction of apoptosis via mitochondrial pathway.
Insights
Epothilone B (Epo B) shows greater cytotoxicity against ovarian cancer cells than paclitaxel. Epo B induces apoptosis through mitochondrial pathways, involving ROS production and calcium level changes.
Area of Science:
- Oncology
- Cell Biology
- Pharmacology
Background:
- Epothilones represent a novel class of microtubule-targeting agents.
- Paclitaxel is a standard treatment for ovarian cancer, but resistance can occur.
Purpose of the Study:
- To compare the effects of epothilone B (Epo B) and paclitaxel (PTX) on ovarian cancer cell metabolism.
- To investigate the mechanism of Epo B's antitumor activity.
Main Methods:
- Comparative analysis of Epo B and PTX on OV-90 (tumor) and MM 14 (normal) ovarian cells.
- Assessment of cytotoxicity, apoptosis markers, cell morphology, mitochondrial membrane potential, cytochrome c release, intracellular calcium levels, and ROS production.
Main Results:
- Epothilone B demonstrated significantly higher cytotoxicity against OV-90 ovarian cancer cells compared to paclitaxel.
- Epo B induced apoptosis, evidenced by changes in cell morphology, mitochondrial membrane potential, and cytochrome c release.
- Reactive oxygen species (ROS) production and a slight increase in intracellular calcium were observed, both linked to Epo B-induced apoptosis via the mitochondrial pathway.
Conclusions:
- Epothilone B is a promising alternative to paclitaxel for ovarian cancer treatment due to its superior efficacy.
- The antitumor activity of Epo B is mediated by the induction of apoptosis through the mitochondrial pathway, involving ROS generation.
Related Concept Videos
The Intrinsic Apoptotic Pathway
The Extrinsic Apoptotic Pathway
Apoptosis
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle
Abnormal Proliferation
